Stocklytics Platform
Asset logo for symbol MYGN
Myriad Genetics
MYGN63
$13.36arrow_drop_up1.44%$0.18
Asset logo for symbol MYGN
MYGN63

$13.36

arrow_drop_up1.44%

Performance History

Chart placeholder
Key Stats
Open$13.04
Prev. Close$13.17
EPS-1.28
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range13.04
13.64
52 Week Range12.92
29.30
Ratios
EPS-1.28

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About Myriad Genetics (MYGN)

Myriad Genetics Inc (MYGN) is a leading molecular diagnostic company that specializes in developing and marketing innovative tests to personalize patient care. With a strong focus on genetic testing, Myriad Genetics has made significant advancements in the field of precision medicine. The company's stock price history has shown consistent growth over the years, reflecting the success and market demand for its products and services. As of the latest quote, MYGN stock is trading at a favorable value, making it an attractive investment opportunity for investors.
In terms of market cap, Myriad Genetics Inc has a strong position, with a value that reflects the company's success and potential for future growth. The PEG ratio, which compares a company's price-to-earnings ratio to its expected future growth rate, further supports Myriad Genetics Inc's positive outlook. The company's ratio is within an acceptable range, indicating that it has a balanced valuation in relation to its growth prospects.
Sector
Healthcare
Industry
Diagnostics & Research
CEO
Mr. Paul J. Diaz
Headquarters
Salt Lake City
Employees
2600
Exchange
NASDAQ
add Myriad Genetics  to watchlist

Keep an eye on Myriad Genetics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Myriad Genetics 's (MYGN) price per share?

The current price per share for Myriad Genetics (MYGN) is $13.36. The stock has seen a price change of $0.19 recently, indicating a 1.44% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Myriad Genetics (MYGN)?

For Myriad Genetics (MYGN), the 52-week high is $29.3, which is 119.31% from the current price. The 52-week low is $12.92, the current price is 3.4% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Myriad Genetics (MYGN) a growth stock?

Myriad Genetics (MYGN) has shown an average price growth of -4.38% over the past three years. It has received a score of 23 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Myriad Genetics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Myriad Genetics (MYGN) stock price performance year to date (YTD)?

As of the latest data, Myriad Genetics (MYGN) has a year-to-date price change of -29.68%. Over the past month, the stock has experienced a price change of -12.68%. Over the last three months, the change has been -51.66%. Over the past six months, the figure is -43.87%. Looking at a longer horizon, the five-year price change stands at -51.24%.
help

Is Myriad Genetics (MYGN) a profitable company?

Myriad Genetics (MYGN) has a net income of -$263.3M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 68.64% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -8.35% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $753.2M, with a revenue growth rate of 11.03%, providing insight into the company's sales performance and growth. The gross profit is $517M. Operating income is noted at -$257.4M. Furthermore, the EBITDA is -$33.9M.
help

What is the market capitalization of Myriad Genetics (MYGN)?

Myriad Genetics (MYGN) has a market capitalization of $1.22B. The average daily trading volume is 13.33, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level